Antibiotic susceptibility of sulfamethoxazole-trimethoprim resistant Stenotrophomonas maltophilia strains isolated at a tertiary care centre in Hungary

Acta Microbiologica et Immunologica Hungarica

Volumn 62, Issue 3, 2015, Pages 295-305

  Juhász, Emese ^a   Pongrácz, Júlia ^a   Iván, Miklós ^a   Kristóf, Katalin ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

Antibiotic resistance; Stenotrophomonas maltophilia; Sulfamethoxazole trimethoprim resistance; Synergism

Indexed keywords

ANTIBIOTIC AGENT; CEFTAZIDIME; CHLORAMPHENICOL; CIPROFLOXACIN; COLISTIN; COTRIMOXAZOLE; DOXYCYCLINE; LEVOFLOXACIN; MOXIFLOXACIN; TIGECYCLINE; ANTIINFECTIVE AGENT; MINOCYCLINE;

ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL INFECTION; BACTERIUM ISOLATION; BROTH DILUTION; CLINICAL ARTICLE; DRUG POTENTIATION; GENETIC SCREENING; HUMAN; HUNGARY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; STENOTROPHOMONAS MALTOPHILIA; TERTIARY CARE CENTER; ANALOGS AND DERIVATIVES; ANTIBIOTIC RESISTANCE; DRUG EFFECTS; GENETICS; GRAM NEGATIVE INFECTION; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; STATISTICS AND NUMERICAL DATA;

ANTI-BACTERIAL AGENTS; CEFTAZIDIME; DRUG RESISTANCE, BACTERIAL; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; HUNGARY; LEVOFLOXACIN; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE; STENOTROPHOMONAS MALTOPHILIA; TERTIARY CARE CENTERS;

EID: 84946038085     PISSN: 12178950     EISSN: 15882640     Source Type: Journal    
DOI: 10.1556/030.62.2015.3.7     Document Type: Article

References (28)

1. Abbott, I. J., Slavin, M. A., Turnidge, J. D., Thursky, K. A., Worth, L. J.: Stenotrophomonas maltophilia: Emerging disease patterns and challenges for treatment. Expert Rev Anti Infect Ther 9(4), 471-488 (2011).
2. Brooke, J. S.: Stenotrophomonas maltophilia: An emerging global opportunistic pathogen. Clin Microbiol Rev 25(1), 2-41 (2012).
3. http://www.eucast.org/clinical+breakpoints/
4. Looney, W. J., Narita, M., Mühlemann, K.: Stenotrophomonas maltophilia: An emerging opportunist human pathogen. Lancet Infect Dis 9(5), 312-323 (2009).
5. Barbolla, R., Catalano, M., Orman, B. E., Famiglietti, A., Vay, C., Smayevsky, J., Centrón, D., Piñeiro, S. A.: Class 1 integrons increase trimethoprim-sulfamethoxazole MICs against epidemiologically unrelated Stenotrophomonas maltophilia isolates. Antimicrob Agents Chemother 48(2), 666-669 (2004).
6. Chang, L. L., Lin, H. H., Chang, C. Y., Lu, P. L.: Increased incidence of class 1 integrons in trimethoprim/sulfamethoxazole-resistant clinical isolates of Stenotrophomonas maltophilia. J Antimicrob Chemother 59(5), 1038-1039 (2007).
7. Hu, L. F., Chang, X., Ye, Y., Wang, Z. X., Shao, Y. B., Shi, W., Li, X., Li, J. B.: Stenotrophomonas maltophilia resistance to trimethoprim/sulfamethoxazole mediated by acquisition of sul and dfrA genes in a plasmid-mediated class 1 integron. Int J Antimicrob Agents 37(3), 230-234 (2011).
8. Hu, L. F., Gao, L. P., Ye, Y., Chen, X., Zhou, X. T., Yang, H. F., Liiu, Y. Y., Mei, Q., Li, J. B.: Susceptibility of Stenotrophomonas maltophilia clinical strains in China to antimicrobial combinations. J Chemother 26(5), 282-286 (2014).
9. Brooke, J. S.: New strategies against Stenotrophomonas maltophilia: A serious worldwide intrinsically drug-resistant opportunistic pathogen. Expert Rev Anti Infect Ther 12(1), 1-4 (2014).
10. San Gabriel, P., Zhou, J., Tabibi, S., Chen, Y., Trauzzi, M., Saiman, L.: Antimicrobial susceptibility and synergy studies of Stenotrophomonas maltophilia isolates from patients with cystic fibrosis. Antimicrob Agents Chemother 48(1), 168-171 (2004).
11. Milne, K. E., Gould, I. M.: Combination antimicrobial susceptibility testing of multidrug-resistant Stenotrophomonas maltophilia from cystic fibrosis patients. Antimicrob Agents Chemother 56(8), 4071-4077 (2012).
12. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility testing. CLSI approved Standard. M100 S16. CLSI, Wayne, PA, USA, 2012.
13. Balke, B., Hogardt, M., Schmoldt, S., Hoy, L., Weissbrodt, H., Häussler, S.: Evaluation of the E test for the assessment of synergy of antibiotic combinations against multiresistant Pseudomonas aeruginosa isolates from cystic fibrosis patients. Eur J Clin Microbiol Infect Dis 25(1), 25-30 (2006).
14. Betts, J. W., Phee, L. M., Woodford, N., Wareham, D. W.: Activity of colistin in combination with tigecycline or rifampicin against multidrug-resistant Stenotrophomonas maltophilia. Eur J Clin Microbiol Infect Dis 33(9), 1565-1572 (2014).
15. Garcia, L. S.: Clinical Microbiology Procedures Handbook. 3rd Edition, ASM Press, Washington DC, 2010, Chapter 5.12.
16. Silbert, S., Pfaller, M. A., Hollis, R. J., Barth, A. L., Sader, H. S.: Evaluation of three molecular typing techniques for nonfermentative Gram-negative bacilli. Infect Control Hosp Epidemiol 25(10), 847-851 (2004).
17. Grape, M., Farra, A., Kronvall, G., Sundström, L.: Integrons and gene cassettes in clinical isolates of co-trimoxazole-resistant Gram-negative bacteria. Clin Microbiol Infect 11(3), 185-192 (2005).
18. Juhász, E., Krizsán, G., Lengyel, G., Grósz, G., Pongrácz, J., Kristóf, K.: Infection and colonization by Stenotrophomonas maltophilia: Antimicrobial susceptibility and clinical background of strains isolated at a tertiary care centre in Hungary. Ann Clin Microbiol Antimicrob 13(1), 333 (2014).
19. Giamarellos-Bourboulis, E. J., Karnesis, L., Galani, I., Giamarellou, H.: In vitro killing effect of moxifloxacin on clinical isolates of Stenotrophomonas maltophilia resistant to trimethoprim-sulfamethoxazole. Antimicrob Agents Chemother 46(12), 3997-3999 (2002).
20. Wu, K., Yau, Y. C., Matukas, L., Waters, V.: Biofilm compared to conventional antimicrobial susceptibility of Stenotrophomonas maltophilia isolates from cystic fibrosis patients. Antimicrob Agents Chemother 57(3), 1546-1548 (2013).
21. Giamarellos-Bourboulis, E. J., Karnesis, L., Giamarellou, H.: Synergy of colistin with rifampin and trimethoprim/sulfamethoxazole on multidrug-resistant Stenotrophomonas maltophilia. Diagn Microbiol Infect Dis 44(3), 259-263 (2002).
22. Church, D., Lloyd, T., Peirano, G., Pitout, J.: Antimicrobial susceptibility and combination testing of invasive Stenotrophomonas maltophilia isolates. Scand J Infect Dis 45(4), 265-270 (2013).
23. Visalli, M. A., Jacobs, M. R., Appelbaum, P. C.: Activities of three quinolones, alone and in combination with extended-spectrum cephalosporins or gentamicin, against Stenotrophomonas maltophilia. Antimicrob Agents Chemother 42(8), 2002-2005 (1998).
24. Entenza, J. M., Moreillon, P.: Tigecycline in combination with other antimicrobials: A review of in vitro, animal and case report studies. Int J Antimicrob Agents 34(1), 8.e1-9 (2009).
25. Gülmez, D., Cakar, A., Sener, B., Karakaya, J., Hasçelik, G.: Comparison of different antimicrobial susceptibility testing methods for Stenotrophomonas maltophilia and results of synergy testing. J Infect Chemother 16(5), 322-328 (2010).
26. Wood, G. C., Underwood, E. L., Croce, M. A., Swanson, J. M., Fabian, T. C.: Treatment of recurrent Stenotrophomonas maltophilia ventilator-associated pneumonia with doxycycline and aerosolized colistin. Ann Pharmacother 44(10), 1665-1668 (2010).
27. Doern, C. D.: When does 2 plus 2 equal 5? A review of antimicrobial synergy testing. J Clin Microbiol 52(12), 4124-4128 (2014).
28. Toleman, M. A., Bennett, P. M., Bennett, D. M., Jones, R. N., Walsh, T. R.: Global emergence of trimethoprim/sulfamethoxazole resistance in Stenotrophomonas maltophilia mediated by acquisition of sul genes. Emerg Infect Dis 13(4), 559-565 (2007).